Kissoon Trisha, Godder Kamar, Fort John
Nicklaus Children's Hospital, Miami.
University of Florida Shands Children's Hospital, Gainesville, FL.
J Pediatr Hematol Oncol. 2020 Apr;42(3):e174-e176. doi: 10.1097/MPH.0000000000001491.
Hematopoietic stem cell transplantation using progenitor cells is a potentially curative treatment option for patients with high-risk malignancies and nonmalignant hematologic, immunologic, and genetic conditions. There is a need for evidence regarding safe practices and controlled infusion processes. Syringe and intravenous infusion pumps are not commonly used to deliver hematopoietic stem cell products (HPCs) due to a paradigm of thought that suggests that the pressure from the pump might damage the HPCs. Here, we describe a retrospective analysis of 114 patients who received HPC infusions using either a syringe or intravenous pump, providing support for this method along with successful engraftment data. This method may be a viable option to obtain reliable and consistent infusion rates, especially in pediatrics. To the best of our knowledge, this is the only study to date demonstrating safely using syringe and intravenous pump mechanisms in the setting of autologous and allogeneic pediatric stem cell transplantation.
使用祖细胞进行造血干细胞移植对于高危恶性肿瘤以及非恶性血液学、免疫学和遗传性疾病患者而言是一种具有潜在治愈可能的治疗选择。目前需要有关安全操作和可控输注过程的证据。由于一种观念认为泵产生的压力可能会损害造血干细胞产品(HPC),注射器和静脉输液泵通常不用于输送造血干细胞产品。在此,我们对114例使用注射器或静脉输液泵接受HPC输注的患者进行了回顾性分析,提供了该方法的支持以及成功植入数据。这种方法可能是获得可靠且一致的输注速率的可行选择,尤其是在儿科。据我们所知,这是迄今为止唯一一项证明在自体和异体儿科干细胞移植中安全使用注射器和静脉输液泵机制的研究。